Editorial: Challenges and strategies in the management of ER/PgR Low-expression breast cancer: exploring fundamentals, clinical insights, and treatment approaches - Scorecard - MDSpire

Editorial: Challenges and strategies in the management of ER/PgR Low-expression breast cancer: exploring fundamentals, clinical insights, and treatment approaches

  • By

  • Takashi Takeshita

  • Vittorio Gebbia

  • San-Gang Wu

  • June 11, 2026

  • 0 min

Share

Clinical Scorecard: Navigating the Difficulties and Solutions in Treating Low ER/PgR Expression Breast Cancer

At a Glance

CategoryDetail
Condition
Key MechanismsRevise to emphasize the heterogeneity and specific characteristics of low ER/PgR tumors.
Target Population
Care Setting

Key Highlights

  • emerging_therapies

Guideline-Based Recommendations

Diagnosis

    Management

    • I
    • n
    • c
    • l
    • u
    • d
    • e
    • s
    • p
    • e
    • c
    • i
    • f
    • i
    • c
    • t
    • h
    • e
    • r
    • a
    • p
    • i
    • e
    • s
    • o
    • r
    • s
    • t
    • r
    • a
    • t
    • e
    • g
    • i
    • e
    • s
    • b
    • a
    • s
    • e
    • d
    • o
    • n
    • t
    • h
    • e
    • l
    • a
    • t
    • e
    • s
    • t
    • e
    • v
    • i
    • d
    • e
    • n
    • c
    • e
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Add details on the limitations of CDK4/6 inhibitors in ER-low patients.

        Clinical Best Practices

        • add_recommendation

        Related Resources & Content

        Original Source(s)

        Editorial: Challenges and strategies in the management of ER/PgR Low-expression breast cancer: exploring fundamentals, clinical insights, and treatment approaches

        • by Takashi Takeshita, Vittorio Gebbia, San-Gang Wu

        • June 11, 2026

        Related Content

        Bulk and single-cell RNA sequencing data identified HMGB3 of chromatin regulators as a breast cancer biomarker associated with the cell cycle

        First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

        Primary large cell neuroendocrine carcinoma of the breast with metastasis in the lymph nodes: a case report and literature review